Contraline Raises $92.5 Million in Series B Funding for ADAM Male Contraceptive Trials

Contraline secured $92.5 million in Series B funding to advance its reversible male contraceptive, ADAM, into late-stage clinical trials. The company aims to bring the first product of its kind to the commercial market, contingent upon the successful completion of Phase III testing.

The funding round provides the capital necessary to scale operations and conduct the rigorous clinical evaluations required for regulatory approval. ADAM functions as a hydrogel implant designed to block sperm transport within the vas deferens, offering a non-hormonal alternative to existing contraceptive methods. If the upcoming trials meet their primary endpoints, the treatment could represent a significant shift in reproductive health options for men. The company plans to utilize these resources to finalize its clinical development program and prepare for potential commercialization.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 3, 2026

Author

GOAI